JP2009512708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009512708A5 JP2009512708A5 JP2008536806A JP2008536806A JP2009512708A5 JP 2009512708 A5 JP2009512708 A5 JP 2009512708A5 JP 2008536806 A JP2008536806 A JP 2008536806A JP 2008536806 A JP2008536806 A JP 2008536806A JP 2009512708 A5 JP2009512708 A5 JP 2009512708A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- laquinimod sodium
- sodium
- laquinimod
- ppm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 20
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 15
- 229960004577 laquinimod Drugs 0.000 claims 15
- 238000000034 method Methods 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 7
- 239000007864 aqueous solution Substances 0.000 claims 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims 4
- 239000012296 anti-solvent Substances 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 4
- 229910001385 heavy metal Inorganic materials 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052708 sodium Inorganic materials 0.000 claims 3
- 239000011734 sodium Substances 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 229910052804 chromium Inorganic materials 0.000 claims 2
- 239000011651 chromium Substances 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72865705P | 2005-10-19 | 2005-10-19 | |
| US60/728,657 | 2005-10-19 | ||
| PCT/US2006/040925 WO2007047863A2 (en) | 2005-10-19 | 2006-10-18 | Crystals of laquinimod sodium, and process for the manufacture thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012277069A Division JP2013100299A (ja) | 2005-10-19 | 2012-12-19 | ラキニモドナトリウムの結晶、及びその製造方法 |
| JP2015152209A Division JP2016020353A (ja) | 2005-10-19 | 2015-07-31 | ラキニモドナトリウムの結晶，及びその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009512708A JP2009512708A (ja) | 2009-03-26 |
| JP2009512708A5 true JP2009512708A5 (enExample) | 2012-03-08 |
| JP5832716B2 JP5832716B2 (ja) | 2015-12-16 |
Family
ID=37963287
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536806A Expired - Fee Related JP5832716B2 (ja) | 2005-10-19 | 2006-10-18 | ラキニモドナトリウムの結晶，及びその製造方法 |
| JP2012277069A Withdrawn JP2013100299A (ja) | 2005-10-19 | 2012-12-19 | ラキニモドナトリウムの結晶、及びその製造方法 |
| JP2015152209A Pending JP2016020353A (ja) | 2005-10-19 | 2015-07-31 | ラキニモドナトリウムの結晶，及びその製造方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012277069A Withdrawn JP2013100299A (ja) | 2005-10-19 | 2012-12-19 | ラキニモドナトリウムの結晶、及びその製造方法 |
| JP2015152209A Pending JP2016020353A (ja) | 2005-10-19 | 2015-07-31 | ラキニモドナトリウムの結晶，及びその製造方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7884208B2 (enExample) |
| EP (2) | EP2687512A1 (enExample) |
| JP (3) | JP5832716B2 (enExample) |
| KR (1) | KR101440982B1 (enExample) |
| CN (3) | CN103333107A (enExample) |
| AR (1) | AR056708A1 (enExample) |
| AU (1) | AU2006304672B2 (enExample) |
| BR (1) | BRPI0617477A2 (enExample) |
| CA (1) | CA2625287C (enExample) |
| DK (1) | DK1937642T3 (enExample) |
| ES (1) | ES2523762T3 (enExample) |
| HR (1) | HRP20141160T1 (enExample) |
| IL (1) | IL190137A (enExample) |
| NZ (2) | NZ592897A (enExample) |
| PL (1) | PL1937642T3 (enExample) |
| PT (1) | PT1937642E (enExample) |
| RS (1) | RS53666B1 (enExample) |
| RU (1) | RU2415841C2 (enExample) |
| SG (1) | SG10201508623RA (enExample) |
| SI (1) | SI1937642T1 (enExample) |
| UA (1) | UA92761C2 (enExample) |
| WO (1) | WO2007047863A2 (enExample) |
| ZA (1) | ZA200803527B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| PT1937642E (pt) * | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| NZ573846A (en) * | 2006-06-12 | 2012-01-12 | Teva Pharma | Stable laquinimod preparations |
| EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2010001257A2 (en) * | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
| WO2010028015A2 (en) * | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| WO2010070449A2 (en) | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| BR112012002124A2 (pt) * | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| DK2467372T3 (en) | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| KR20130036217A (ko) * | 2010-03-03 | 2013-04-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 관절염의 치료 |
| BR112012021905A2 (pt) * | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| BR112012022187A2 (pt) * | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| KR20130092558A (ko) * | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| CA2815935A1 (en) | 2010-11-28 | 2012-05-31 | Mapi Pharma Ltd. | Intermediate compounds and processes for the preparation of quinoline derivatives such as laquinimod sodium |
| US8889627B2 (en) * | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| AU2013221304B2 (en) * | 2012-02-16 | 2017-12-21 | Teva Pharmaceutical Industries Ltd. | N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
| CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
| JP5979232B2 (ja) | 2012-09-03 | 2016-08-24 | トヨタ自動車株式会社 | 衝突判定装置及び衝突判定方法 |
| EA201590788A1 (ru) | 2012-11-07 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Аминные соли лахинимода |
| MX2015010967A (es) | 2013-03-14 | 2015-10-26 | Teva Pharma | Formulaciones transdermicas de laquinimod. |
| AU2014236232A1 (en) * | 2013-03-14 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| TWI846166B (zh) | 2013-11-15 | 2024-06-21 | 美商阿克比治療有限公司 | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 |
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
| JP2022130270A (ja) * | 2021-02-25 | 2022-09-06 | シンバイオシス株式会社 | 腸管吸収用補助剤及びその利用方法 |
| KR102876408B1 (ko) * | 2022-01-24 | 2025-10-24 | 한국과학기술원 | 입도가 조절된 헥사나이트로스틸벤 타입 iv의 제조방법 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613574A (en) * | 1898-11-01 | Feed-regulator | ||
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
| DE4120646A1 (de) * | 1991-06-22 | 1992-12-24 | Bayer Ag | 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6256814B1 (en) | 1997-09-19 | 2001-07-10 | Cosco Management, Inc. | Playyard |
| US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| YU86001A (sh) | 1999-06-07 | 2004-07-15 | Altana Pharma Ag. | Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| PL199781B1 (pl) | 1999-10-25 | 2008-10-31 | Active Biotech Ab | Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania |
| JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| EP1386926A1 (en) | 2002-07-29 | 2004-02-04 | Bioxtal | Methods for producing labelled recombinant polypeptides and uses thereof |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| AU2003300692A1 (en) | 2003-10-30 | 2005-05-19 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| PT1937642E (pt) | 2005-10-19 | 2014-11-25 | Teva Pharma | Cristais de sódio de laquinimod, e processos para o fabrico dos mesmos |
| NZ573846A (en) | 2006-06-12 | 2012-01-12 | Teva Pharma | Stable laquinimod preparations |
| EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| WO2010001257A2 (en) | 2008-07-01 | 2010-01-07 | Actavis Group Ptc Ehf | Novel solid state forms of laquinimod and its sodium salt |
| WO2010028015A2 (en) | 2008-09-03 | 2010-03-11 | Auspex Pharmaceuticals, Inc | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| BR112012002124A2 (pt) | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| DK2467372T3 (en) | 2009-08-10 | 2016-08-22 | Teva Pharma | TREATMENT OF BDNF-RELATED DISEASES USING LAQUINIMOD |
| BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| BR112012022187A2 (pt) | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| KR20130036217A (ko) | 2010-03-03 | 2013-04-11 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 관절염의 치료 |
| KR20130092558A (ko) | 2010-07-09 | 2013-08-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 중수소화된 n-에틸-n-페닐-1,2-다이하이드로-4-하이드록시-5-클로로-1-메틸-2-옥소퀴놀린-3-카복스아마이드, 그의 염 및 용도 |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| US20120055072A1 (en) * | 2010-09-08 | 2012-03-08 | Rankin Sammy D | Directional guide for fishing lures |
| MX2013006464A (es) | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
-
2006
- 2006-10-18 PT PT68262971T patent/PT1937642E/pt unknown
- 2006-10-18 NZ NZ592897A patent/NZ592897A/xx unknown
- 2006-10-18 SG SG10201508623RA patent/SG10201508623RA/en unknown
- 2006-10-18 PL PL06826297T patent/PL1937642T3/pl unknown
- 2006-10-18 CA CA2625287A patent/CA2625287C/en not_active Expired - Fee Related
- 2006-10-18 DK DK06826297.1T patent/DK1937642T3/en active
- 2006-10-18 WO PCT/US2006/040925 patent/WO2007047863A2/en not_active Ceased
- 2006-10-18 BR BRPI0617477-9A patent/BRPI0617477A2/pt not_active Application Discontinuation
- 2006-10-18 EP EP13153698.9A patent/EP2687512A1/en not_active Withdrawn
- 2006-10-18 HR HRP20141160TT patent/HRP20141160T1/hr unknown
- 2006-10-18 ES ES06826297.1T patent/ES2523762T3/es active Active
- 2006-10-18 JP JP2008536806A patent/JP5832716B2/ja not_active Expired - Fee Related
- 2006-10-18 AU AU2006304672A patent/AU2006304672B2/en not_active Ceased
- 2006-10-18 NZ NZ567088A patent/NZ567088A/en unknown
- 2006-10-18 SI SI200631860T patent/SI1937642T1/sl unknown
- 2006-10-18 UA UAA200806003A patent/UA92761C2/ru unknown
- 2006-10-18 CN CN2013102471796A patent/CN103333107A/zh active Pending
- 2006-10-18 ZA ZA200803527A patent/ZA200803527B/xx unknown
- 2006-10-18 CN CN200680039201.6A patent/CN101291911B/zh not_active Expired - Fee Related
- 2006-10-18 CN CN201710533188.XA patent/CN107176923A/zh active Pending
- 2006-10-18 RS RS20140629A patent/RS53666B1/sr unknown
- 2006-10-18 US US11/583,282 patent/US7884208B2/en not_active Expired - Fee Related
- 2006-10-18 RU RU2008119456/04A patent/RU2415841C2/ru not_active IP Right Cessation
- 2006-10-18 KR KR1020087011727A patent/KR101440982B1/ko not_active Expired - Fee Related
- 2006-10-18 EP EP06826297.1A patent/EP1937642B1/en active Active
- 2006-10-19 AR ARP060104574A patent/AR056708A1/es unknown
-
2008
- 2008-03-13 IL IL190137A patent/IL190137A/en not_active IP Right Cessation
-
2011
- 2011-01-21 US US13/011,233 patent/US8647646B2/en not_active Expired - Fee Related
- 2011-01-21 US US13/011,187 patent/US8673322B2/en not_active Expired - Fee Related
-
2012
- 2012-12-19 JP JP2012277069A patent/JP2013100299A/ja not_active Withdrawn
-
2014
- 2014-02-20 US US14/185,470 patent/US20140171647A1/en not_active Abandoned
-
2015
- 2015-07-31 JP JP2015152209A patent/JP2016020353A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009512708A5 (enExample) | ||
| HRP20141160T1 (hr) | Kristali natrijevog lakvinimoda i postupak za njihovu proizvodnju | |
| Joshi et al. | Herbal extracts of Tribulus terrestris and Bergenia ligulata inhibit growth of calcium oxalate monohydrate crystals in vitro | |
| KR100311165B1 (ko) | 프라미펠솔을 함유하는 우울증 치료용 약제학적 조성물 | |
| JP2017526699A (ja) | （６ｓ）−５−メチルテトラヒドロ葉酸又はその塩の組成物及びその調製と応用 | |
| BRPI0506906B1 (pt) | Composição farmacêutica sólida estável contendo sal de um derivado de 3-quinolinacarboxamida, e processos para a estabilização de um sal, e para a preparação de um sal cristalino | |
| CN106279121B (zh) | 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途 | |
| JP2006528221A5 (enExample) | ||
| JPH02268178A (ja) | ３―ホルミルアミノ―７―メチルスルホニルアミノ―６―フェノキシ―４ｈ―１―ベンゾピラン―４―オンまたはその塩を含有する抗炎症製剤 | |
| TW201030155A (en) | Method for manufacturing high-purity erbium, high-purity erbium, sputtering target composed of high-purity erbium, and metal gate film having high-purity erbium as main component | |
| CN105985394B (zh) | 一种索非布韦新晶型及其制备方法 | |
| Raybin | A new color reaction with sucrose | |
| CA1201923A (en) | Acesulfam-containing compositions, tablets on the basis thereof and process for the manufacture of these tablets | |
| CN107693494B (zh) | 一种孟鲁司特钠颗粒组合物及其制备方法 | |
| CN105253903A (zh) | 一种三元复合沉淀剂及其用于高镁锂比卤水锂镁分离 | |
| RS60172B1 (sr) | Farmaceutska kompozicija u obliku oralne suspenzije, koja uključuje flavonoidnu frakciju i ksantan gumu | |
| CN107106568B (zh) | 稠合氨基二氢噻嗪衍生物的药物组合物 | |
| HRP20110093T1 (hr) | Kristalna baza escitaloprama i orodisperzibilne tablete koje sadrže bazu escitaloprama | |
| CN101054393B (zh) | 阿德福韦酯无水结晶物、其制备方法以及药物组合物 | |
| WO2015078845A1 (en) | Pharmaceutical composition comprising amorphous ivabradine | |
| CN109320553B (zh) | 用于抗病毒的核苷类逆转录酶抑制剂 | |
| CN104382870A (zh) | 一种含有波拉克林钾-帕罗西汀的复合物 | |
| JPS63119426A (ja) | 肝疾患治療薬組成物 | |
| Gligor et al. | ASSESSMENT OF THE EFFECTS OF IBUPROFEN ASSOCIATION WITH NIFEDIPINE ON IBUPROFEN INDUCED HEPATOTOXICITY | |
| WO2006090263A1 (en) | Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions |